Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Artificial Intelligence in Drug Screening Market by Product Type (Immunoassay Analyzers, Breathalyzer, Rapid Test Device, Assay Kits, Chromatography Instruments), by Sample type (Urine, Hair, Oral, Others) and by End User (Workplace, Hospital, Criminal Justice): Global Opportunity Analysis and Industry Forecast, 2023-2032

A04873

Pages: NA

Charts: NA

Tables: NA

Artificial intelligence (AI) is an area of computer science that emphasizes on the creation of intelligent computers to perform tasks like humans. Artificial intelligence offers activities such as speech recognition, learning, planning, problem solving, and others. It can also be applied in the field of drug screening. Drug screening is a process of chemical analysis designed to test patients for drug abuse. It is a vital process as drug abuse is a serious public health problem that affects brain and behavior of an individual. This process is also employed in workplaces to avoid hiring of drug addict candidates and to provide a safe workplace to other employees. Artificial intelligence has made it possible to screen drug abuse candidates in shorter period, moreover it also plays a great role in treatment of patients with drug addiction.

Increase in alcohol consumption worldwide, rise in use of narcotics and illicit drugs across the globe, stringent government laws for drug screening, rise in adoption of AI systems, and technological advancements in the field of drug screening are anticipated to drive the demand for the adoption of artificial intelligence, which in turn is expected to boost the growth of the artificial intelligence in drug screening market. In addition, other factors expected to drive the growth of the market include the precision in results delivered by AI in drug screening and surge in healthcare expenditure along with the economic development across the globe. In addition, increase in governmental funding to control drug trafficking provides lucrative opportunities for the growth of the market. Conversely, an imprecise regulatory scenario and reluctance among healthcare professionals to adopt AI-based technologies are expected to hamper the artificial intelligence in drug screening market growth.

The global artificial intelligence in drug screening market is segmented across four main categoriesproduct type, sample type, end user, and region. Based on product type, the market is divided into immunoassay analyzers, breathalyzer, rapid test device, assay kits, and chromatography instruments. On the basis of sample type, the market is classified into urine, hair, oral, and others. Based on end user, the market is segmented into workplace, criminal justice, and hospital. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).

Key Benefits For Stakeholders:

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.

 Key Market Segments

  • By Product Type
    • Immunoassay Analyzers
    • Breathalyzer
    • Rapid Test Device
    • Assay Kits
    • Chromatography Instruments
  • By Sample type
    • Urine
    • Hair
    • Oral
    • Others
  • By End User
    • Workplace
    • Hospital
    • Criminal Justice
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Alere, Inc.
  • Thermo Fisher Scientific, Inc.
  • Abbott Laboratories
  • Siemens AG
  • Danaher Corporation
  • Hoffmann-La Roche AG
  • Drgerwerk AG & Co. KGAA
  • Biorad Laboratories, Inc.
  • Quest Diagnostics Incorporated
  • Express Diagnostics International Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Immunoassay Analyzers

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Breathalyzer

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Rapid Test Device

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Assay Kits

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Chromatography Instruments

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET, BY SAMPLE TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Sample Type

    • 5.2. Urine

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Hair

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Oral

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Workplace

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Hospital

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Criminal Justice

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product Type

      • 7.2.3. Market Size and Forecast, By Sample Type

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Artificial Intelligence In Drug Screening Market

        • 7.2.6.1. Market Size and Forecast, By Product Type
        • 7.2.6.2. Market Size and Forecast, By Sample Type
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Artificial Intelligence In Drug Screening Market

        • 7.2.7.1. Market Size and Forecast, By Product Type
        • 7.2.7.2. Market Size and Forecast, By Sample Type
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Artificial Intelligence In Drug Screening Market

        • 7.2.8.1. Market Size and Forecast, By Product Type
        • 7.2.8.2. Market Size and Forecast, By Sample Type
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product Type

      • 7.3.3. Market Size and Forecast, By Sample Type

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Artificial Intelligence In Drug Screening Market

        • 7.3.6.1. Market Size and Forecast, By Product Type
        • 7.3.6.2. Market Size and Forecast, By Sample Type
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Artificial Intelligence In Drug Screening Market

        • 7.3.7.1. Market Size and Forecast, By Product Type
        • 7.3.7.2. Market Size and Forecast, By Sample Type
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Artificial Intelligence In Drug Screening Market

        • 7.3.8.1. Market Size and Forecast, By Product Type
        • 7.3.8.2. Market Size and Forecast, By Sample Type
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Artificial Intelligence In Drug Screening Market

        • 7.3.9.1. Market Size and Forecast, By Product Type
        • 7.3.9.2. Market Size and Forecast, By Sample Type
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Artificial Intelligence In Drug Screening Market

        • 7.3.10.1. Market Size and Forecast, By Product Type
        • 7.3.10.2. Market Size and Forecast, By Sample Type
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Artificial Intelligence In Drug Screening Market

        • 7.3.11.1. Market Size and Forecast, By Product Type
        • 7.3.11.2. Market Size and Forecast, By Sample Type
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Artificial Intelligence In Drug Screening Market

        • 7.3.12.1. Market Size and Forecast, By Product Type
        • 7.3.12.2. Market Size and Forecast, By Sample Type
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product Type

      • 7.4.3. Market Size and Forecast, By Sample Type

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Artificial Intelligence In Drug Screening Market

        • 7.4.6.1. Market Size and Forecast, By Product Type
        • 7.4.6.2. Market Size and Forecast, By Sample Type
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Artificial Intelligence In Drug Screening Market

        • 7.4.7.1. Market Size and Forecast, By Product Type
        • 7.4.7.2. Market Size and Forecast, By Sample Type
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Artificial Intelligence In Drug Screening Market

        • 7.4.8.1. Market Size and Forecast, By Product Type
        • 7.4.8.2. Market Size and Forecast, By Sample Type
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Artificial Intelligence In Drug Screening Market

        • 7.4.9.1. Market Size and Forecast, By Product Type
        • 7.4.9.2. Market Size and Forecast, By Sample Type
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Artificial Intelligence In Drug Screening Market

        • 7.4.10.1. Market Size and Forecast, By Product Type
        • 7.4.10.2. Market Size and Forecast, By Sample Type
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Artificial Intelligence In Drug Screening Market

        • 7.4.11.1. Market Size and Forecast, By Product Type
        • 7.4.11.2. Market Size and Forecast, By Sample Type
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Artificial Intelligence In Drug Screening Market

        • 7.4.12.1. Market Size and Forecast, By Product Type
        • 7.4.12.2. Market Size and Forecast, By Sample Type
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Artificial Intelligence In Drug Screening Market

        • 7.4.13.1. Market Size and Forecast, By Product Type
        • 7.4.13.2. Market Size and Forecast, By Sample Type
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Artificial Intelligence In Drug Screening Market

        • 7.4.14.1. Market Size and Forecast, By Product Type
        • 7.4.14.2. Market Size and Forecast, By Sample Type
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product Type

      • 7.5.3. Market Size and Forecast, By Sample Type

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Artificial Intelligence In Drug Screening Market

        • 7.5.6.1. Market Size and Forecast, By Product Type
        • 7.5.6.2. Market Size and Forecast, By Sample Type
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Artificial Intelligence In Drug Screening Market

        • 7.5.7.1. Market Size and Forecast, By Product Type
        • 7.5.7.2. Market Size and Forecast, By Sample Type
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Artificial Intelligence In Drug Screening Market

        • 7.5.8.1. Market Size and Forecast, By Product Type
        • 7.5.8.2. Market Size and Forecast, By Sample Type
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Artificial Intelligence In Drug Screening Market

        • 7.5.9.1. Market Size and Forecast, By Product Type
        • 7.5.9.2. Market Size and Forecast, By Sample Type
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Artificial Intelligence In Drug Screening Market

        • 7.5.10.1. Market Size and Forecast, By Product Type
        • 7.5.10.2. Market Size and Forecast, By Sample Type
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Artificial Intelligence In Drug Screening Market

        • 7.5.11.1. Market Size and Forecast, By Product Type
        • 7.5.11.2. Market Size and Forecast, By Sample Type
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Alere, Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Drgerwerk AG And Co. KGAA

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Abbott Laboratories

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Hoffmann-La Roche AG

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Biorad Laboratories, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Siemens AG

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Thermo Fisher Scientific, Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Danaher Corporation

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Quest Diagnostics Incorporated

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Express Diagnostics International Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR BREATHALYZER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR RAPID TEST DEVICE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR ASSAY KITS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR CHROMATOGRAPHY INSTRUMENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR URINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR HAIR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR ORAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR WORKPLACE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR HOSPITAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR CRIMINAL JUSTICE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. U.S. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 22. U.S. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 23. U.S. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. CANADA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 25. CANADA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 26. CANADA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 29. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 33. EUROPE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 36. FRANCE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 39. GERMANY ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. ITALY ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 41. ITALY ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 42. ITALY ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 45. SPAIN ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. UK ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 47. UK ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 48. UK ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 51. RUSSIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 54. REST OF EUROPE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 58. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. CHINA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 60. CHINA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 61. CHINA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 64. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. INDIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 66. INDIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 67. INDIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 70. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 73. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 76. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 79. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 82. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 89. LAMEA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 92. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 95. SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 98. SAUDI ARABIA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. UAE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 100. UAE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 101. UAE ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 104. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY SAMPLE TYPE, 2025-2033 ($MILLION)
  • TABLE 107. REST OF LAMEA ARTIFICIAL INTELLIGENCE IN DRUG SCREENING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 108. ALERE, INC.: KEY EXECUTIVES
  • TABLE 109. ALERE, INC.: COMPANY SNAPSHOT
  • TABLE 110. ALERE, INC.: OPERATING SEGMENTS
  • TABLE 111. ALERE, INC.: PRODUCT PORTFOLIO
  • TABLE 112. ALERE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. DRGERWERK AG AND CO. KGAA: KEY EXECUTIVES
  • TABLE 114. DRGERWERK AG AND CO. KGAA: COMPANY SNAPSHOT
  • TABLE 115. DRGERWERK AG AND CO. KGAA: OPERATING SEGMENTS
  • TABLE 116. DRGERWERK AG AND CO. KGAA: PRODUCT PORTFOLIO
  • TABLE 117. DRGERWERK AG AND CO. KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 119. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 120. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 121. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 122. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 124. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 125. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 126. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 127. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. BIORAD LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 129. BIORAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 130. BIORAD LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 131. BIORAD LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 132. BIORAD LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. SIEMENS AG: KEY EXECUTIVES
  • TABLE 134. SIEMENS AG: COMPANY SNAPSHOT
  • TABLE 135. SIEMENS AG: OPERATING SEGMENTS
  • TABLE 136. SIEMENS AG: PRODUCT PORTFOLIO
  • TABLE 137. SIEMENS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
  • TABLE 139. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 140. THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 141. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 142. THERMO FISHER SCIENTIFIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 144. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 145. DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 146. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 147. DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. QUEST DIAGNOSTICS INCORPORATED: KEY EXECUTIVES
  • TABLE 149. QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT
  • TABLE 150. QUEST DIAGNOSTICS INCORPORATED: OPERATING SEGMENTS
  • TABLE 151. QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 152. QUEST DIAGNOSTICS INCORPORATED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. EXPRESS DIAGNOSTICS INTERNATIONAL INC.: KEY EXECUTIVES
  • TABLE 154. EXPRESS DIAGNOSTICS INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 155. EXPRESS DIAGNOSTICS INTERNATIONAL INC.: OPERATING SEGMENTS
  • TABLE 156. EXPRESS DIAGNOSTICS INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 157. EXPRESS DIAGNOSTICS INTERNATIONAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET
  • FIGURE 3. SEGMENTATION ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET
  • FIGURE 11. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR BREATHALYZER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR RAPID TEST DEVICE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR ASSAY KITS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR CHROMATOGRAPHY INSTRUMENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET SEGMENTATION, BY BY SAMPLE TYPE
  • FIGURE 18. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR URINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR HAIR, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR ORAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET SEGMENTATION, BY BY END USER
  • FIGURE 23. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR WORKPLACE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR HOSPITAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET FOR CRIMINAL JUSTICE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: ARTIFICIAL INTELLIGENCE IN DRUG SCREENING MARKET
  • FIGURE 32. TOP PLAYER POSITIONING, 2024
  • FIGURE 33. ALERE, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. ALERE, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. ALERE, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. DRGERWERK AG AND CO. KGAA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. DRGERWERK AG AND CO. KGAA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. DRGERWERK AG AND CO. KGAA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. HOFFMANN-LA ROCHE AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. BIORAD LABORATORIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. BIORAD LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. BIORAD LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. SIEMENS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. SIEMENS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. SIEMENS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. DANAHER CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. QUEST DIAGNOSTICS INCORPORATED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. QUEST DIAGNOSTICS INCORPORATED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. QUEST DIAGNOSTICS INCORPORATED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. EXPRESS DIAGNOSTICS INTERNATIONAL INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. EXPRESS DIAGNOSTICS INTERNATIONAL INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. EXPRESS DIAGNOSTICS INTERNATIONAL INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Artificial Intelligence in Drug Screening Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved